Cargando…
Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study
INTRODUCTION: Mitotane, the only drug approved by the Food and Drug Administration (FDA) for the treatment of adrenocortical carcinoma, is associated with several side effects including neurotoxicity. The aim of our study is to investigate the relationship between mitotane plasma levels and neurolog...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461107/ https://www.ncbi.nlm.nih.gov/pubmed/37645432 http://dx.doi.org/10.3389/fonc.2023.1222002 |